Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: “Real‐world” evidence
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cardiology"
DOI: 10.1002/clc.23898
Abstract: Cardiovascular medications are vital for the secondary prevention of coronary arterial disease (CAD). However, the effect of cardiovascular medication may depend on the optimal adherence of the patients. This meta‐analysis aims to determine the magnitude… read more here.
Keywords: adherence; arterial disease; coronary arterial; cardiovascular medications ... See more keywords
Effects of cardiovascular medications on primary patency of hemodialysis arteriovenous fistula
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-69019-6
Abstract: While the patency of vascular access is essential for hemodialysis patients, optimal pharmaceutical treatment to maintain arteriovenous fistula (AVF) patency remains lacking. As cardiovascular diseases are highly prevalent in patients with end-stage renal disease, various… read more here.
Keywords: patency; antiplatelet; cardiovascular medications; group ... See more keywords
Evaluation of the efficacy and safety of text messages targeting adherence to cardiovascular medications in secondary prevention: the txt2heart Colombia randomised controlled trial protocol
Sign Up to like & getrecommendations! Published in 2019 at "BMJ Open"
DOI: 10.1136/bmjopen-2018-028017
Abstract: Introduction Anti-platelet therapy, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta-blockers and statins are cost-effective in patients with atherosclerotic cardiovascular diseases (ASCVD) for reducing the risk of ASCVD events. Unfortunately, there is abundant evidence that adherence… read more here.
Keywords: trial; adherence cardiovascular; cardiovascular medications; txt2heart ... See more keywords
Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-061686
Abstract: Objective To synthesise the current knowledge on barriers and facilitators to deprescribing cardiovascular medications (CVMs) at the levels of patients, informal caregivers and healthcare providers (HCPs). Design/setting We conducted a systematic review of studies exploring/assessing… read more here.
Keywords: barriers facilitators; deprescribing cardiovascular; systematic review; facilitators deprescribing ... See more keywords
Abstract 17252: Rates and Predictors of Co-Prescribing Common Interacting Cardiovascular Medications in Atrial Fibrillation Patients on Direct Oral Anticoagulants
Sign Up to like & getrecommendations! Published in 2020 at "Circulation"
DOI: 10.1161/circ.142.suppl_3.17252
Abstract: Introduction: Amiodarone and diltiazem are commonly prescribed cardiovascular medications in atrial fibrillation (AF) patients who take direct oral anticoagulants (DOACs). They are known to have drug-drug interactions (DDIs) with DOACs, increasing serum levels of DOACs… read more here.
Keywords: fibrillation patients; oral anticoagulants; direct oral; medications atrial ... See more keywords
Mitochondrial Effects of Common Cardiovascular Medications: The Good, the Bad and the Mixed
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms232113653
Abstract: Mitochondria are central organelles in the homeostasis of the cardiovascular system via the integration of several physiological processes, such as ATP generation via oxidative phosphorylation, synthesis/exchange of metabolites, calcium sequestration, reactive oxygen species (ROS) production/buffering… read more here.
Keywords: good bad; medications good; mitochondrial effects; effects common ... See more keywords